Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Otago Medical School staff profiles

Dr Kenny Chitcholtan

PositionResearch Fellow
DepartmentDepartment of Obstetrics and Gynaecology (Christchurch)
QualificationsPhD
Research summaryOvarian and endometrial cancer

Research

My research interests are focusing on the activity of tyrosine kinases, targeted inhibitors, effects of ascitic fluid ,and anti-tumour properties of natural food compounds in the progression of advanced ovarian cancer. To understand these factors, I am using three dimensional (3D) cell cultures, chicken embryos and a syngeneic mouse model to investigate the biological activity in ovarian cancer.

Publications

Hassan, W., Chitcholtan, K., Sykes, P., & Garrill, A. (2018). Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells. Cancer Letters, 420, 168-181. doi: 10.1016/j.canlet.2018.02.013

Hassan, W., Chitcholtan, K., Sykes, P., & Garrill, A. (2016). A combination of two receptor tyrosine kinase inhibitors, canertinib and PHA665752 comprises ovarian cancer cell growth in 3D cell models. Oncology & Therapy, 4(2), 257-274. doi: 10.1007/s40487-016-0031-1

Tino, A. B., Chitcholtan, K., Sykes, P. H., & Garrill, A. (2016). Resveratrol and acetyl-resveratrol modulate activity of VEGF and IL-8 in ovarian cancer cell aggregates via attenuation of the NF-κB protein. Journal of Ovarian Research, 9, 84. doi: 10.1186/s13048-016-0293-0

Hogg, S. J., Evans, J. J., Sykes, P. H., & Chitcholtan, K. (2015). A method to investigate the anti-metabolic activity of anti-cancer agents on ovarian cancer cells cultured in a 96-well high throughput format. Journal of Ovarian Research, 8, 43. doi: 10.1186/s13048-015-0172-0

Hogg, S. J., Chitcholtan, K., Hassan, W., Sykes, P. H., & Garrill, A. (2015). Resveratrol, acetyl-resveratrol, and polydatin exhibit antigrowth activity against 3D cell aggregates of the SKOV-3 and OVCAR-8 ovarian cancer cell lines. Obstetrics & Gynecology International, 2015, 279591. doi: 10.1155/2015/279591

Journal - Research Article

Hassan, W., Chitcholtan, K., Sykes, P., & Garrill, A. (2018). Ascitic fluid from advanced ovarian cancer patients compromises the activity of receptor tyrosine kinase inhibitors in 3D cell clusters of ovarian cancer cells. Cancer Letters, 420, 168-181. doi: 10.1016/j.canlet.2018.02.013

Hassan, W., Chitcholtan, K., Sykes, P., & Garrill, A. (2016). A combination of two receptor tyrosine kinase inhibitors, canertinib and PHA665752 comprises ovarian cancer cell growth in 3D cell models. Oncology & Therapy, 4(2), 257-274. doi: 10.1007/s40487-016-0031-1

Tino, A. B., Chitcholtan, K., Sykes, P. H., & Garrill, A. (2016). Resveratrol and acetyl-resveratrol modulate activity of VEGF and IL-8 in ovarian cancer cell aggregates via attenuation of the NF-κB protein. Journal of Ovarian Research, 9, 84. doi: 10.1186/s13048-016-0293-0

Hogg, S. J., Chitcholtan, K., Hassan, W., Sykes, P. H., & Garrill, A. (2015). Resveratrol, acetyl-resveratrol, and polydatin exhibit antigrowth activity against 3D cell aggregates of the SKOV-3 and OVCAR-8 ovarian cancer cell lines. Obstetrics & Gynecology International, 2015, 279591. doi: 10.1155/2015/279591

Hogg, S. J., Evans, J. J., Sykes, P. H., & Chitcholtan, K. (2015). A method to investigate the anti-metabolic activity of anti-cancer agents on ovarian cancer cells cultured in a 96-well high throughput format. Journal of Ovarian Research, 8, 43. doi: 10.1186/s13048-015-0172-0

Chitcholtan, K., Asselin, E., Parent, S., Sykes, P. H., & Evans, J. J. (2013). Differences in growth properties of endometrial cancer in three dimensional (3D) culture and 2D cell monolayer. Experimental Cell Research, 319(1), 75-87. doi: 10.1016/j.yexcr.2012.09.012

Chitcholtan, K., Sykes, P. H., & Evans, J. J. (2012). The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer. Journal of Translational Medicine, 10(1), 38-53. doi: 10.1186/1479-5876-10-38

More publications...